Gelesis Holdings, Inc. (GLS)


0.00 (0.00%)
Symbol GLS
Price $0.1586
Beta 0.994
Volume Avg. 0.57M
Market Cap 11.631M
Shares () -
52 Week Range 0.012-5.67
1y Target Est -
DCF Unlevered GLS DCF ->
DCF Levered GLS LDCF ->
ROE -1744909.49% Strong Sell
ROA -42276138.03% Strong Sell
Operating Margin -
Debt / Equity -462.12% Strong Sell
P/E -0.12 Neutral
P/B -0.44 Neutral


Consensus EPS

Upgrades & Downgrades

Latest GLS news

Mr. Yishai Zohar
New York Stock Exchange

Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.